Clerk of the House of Representatives	Secretary of the Senate
Legislative Resource Center	Office of Public Records
135 Cannon Building	232 Hart Building
Washington, DC 20515	Washington, DC 20510
http://lobbyingdisclosure.house.gov	http://www.senate.gov/lobby

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

 Registrant Name Organization/Lobbying Firm Self Employed Individual JOHNSON & JOHNSON SERVICES, INC. 	
2. Address Address1 ONE JOHNSON & JOHNSON PLAZA	Address2
City <u>NEW BRUNSWICK</u> State	NJ Zip Code 08933 Country USA
3. Principal place of business (if different than line 2)	
City State	Zip Code Country
4a. Contact Name b. Telephone Numb	c. E-mail 5. Senate ID# 20686-12
7. Client Name Self Check if client is a state or local JOHNSON & JOHNSON SERVICES, INC.	government or instrumentality 6. House ID# 303480000
TYPE OF REPORT 8. Year 2024 Q1 (1/1 - 3/31)	Q2 (4/1 - 6/30) Q3 (7/1 - 9/30) Q4 (10/1 - 12/31)
9. Check if this filing amends a previously filed version of this report Image: Check if this is a Termination Report 10. Check if this is a Termination Report Image: Termination Report	ion Date 11. No Lobbying Issue Activity
INCOME OR EXPENSES - YO	OU MUST complete either Line 12 or Line 13
12. Lobbying INCOME relating to lobbying activities for this reporting period was: Less than \$5.000	13. Organizations EXPENSE relating to lobbying activities for this reporting period were: Less than \$5,000
\$5.000 or more \$	\$5,000 or more S 1,120,000.00
Provide a good faith estimate, rounded to the nearest \$10,000, of all lobbying related income for t client (including all payments to the registrant by any other entity for lobbying activities on behal of the client).	
	Method A. Reporting amounts using LDA definitions only
	Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code
	Method C. Reporting amounts under section 162(e) of the Internal Revenue Code
Signature Digitally Signed By: Jane Adams	Date 7/22/2024 11:36:37

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BUD

16. Specific lobbying issues

Issues related to:

Contact lens safety, peripheral artery disease, and stroke care, specifically to provisions regarding appropriations report language Appropriations for Labor Health and Human Services • NIH funding

17. House(s) of Congress and Federal agencies 🗌 Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Deana	McRae			
Timothy	Swope			
Leif	Brierley			
Larry	Camm			
Jane	Adams			
Colleen	Vivaldi			

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code HCR

16. Specific lobbying issues

- S 1375/HR 830, "HELP Copays Act", regarding all provisions.
- PL 117-169, "The Inflation Reduction Act", regarding provisions impacting drug pricing and implementation.
- PL 113-5 "Pandemic All Hazards Preparedness Reauthorization", regarding all provisions.
- \$ 1355/HR 2940, "PASTEUR Act", regarding all provisions.
- HR 3723, "Medical Device Electronic Labeling Act", regarding all provisions.
- HR 2748, "Contact Lens Prescription Verification Modernization Act", regarding all provisions.
- HR 4261, "Amputation Reduction and Compassion Act", regarding all provisions.
- S 3131/HR 5539, "ORPHAN Cures Act", regarding all provisions.
- HR 5372, "Expanding Access to Seniors Access to Lower Cost Medicines Act of 2023", regarding all provisions.
- S 2305, "The Biosimilar Red Tape Elimination Act", regarding all provisions.
- HR 1352, "Increasing Access to Biosimilars Act of 2023", regarding all provisions.
- HR 7174, "Ensuring Pathways to Innovative Cures (EPIC) Act", regarding all provisions
- HR 8574, the "340B Affording Care for Communities and Ensuring a Strong Safety-Net (ACCESS) Act", regarding all provisions
- HR 7384, "Creating Hope Reauthorization Act", regarding all provisions
Issues related to:
- Obesity
- Biosimilars
- Health equity and diversity in clinical trials
- Myopia
- Ambulatory surgical services
- Access to sterilization capacity for medical technologies
- Peripheral artery disease
- Cardiovascular health
- Stroke care
- FDA medical device shortage reporting requirements
- Alternative funding programs
- PBM practices
- Health care workforce wellbeing
- Medicaid Drug Rebate Program
- the SUSTAIN 340B Act

17. House(s) of Congress and Federal agencies 🗌 Check if None

U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Office of Management & Budget (OMB)

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Deana	McRae			
Leif	Brierley			
Larry	Camm			
Timothy	Swope			
Riley	Swinehart			
Wendy	Sussman			
Meghan	Stone			
Amy	Pellegrino			
Kelly	Waters			
Emely	Sanchez			
Abigail	Pinkele			
Jane	Adams			
Colleen	Vivaldi			
David	Kavanaugh			

19. Interest of each foreign entity in the specific issues listed on line 16 above 🖉 Check if None

1

LD-2 Disclosure Form

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code l	LBR			
16. Specific lobbying issues				
- Issues related to diversity,	equity and inclusion.			
17. House(s) of Congress an	d Federal agencies 🗌 Check if None			
U.S. HOUSE OF REPRESE	NTATIVES, Federal Trade Commission (FTC)			
18. Name of each individual	who acted as a lobbyist in this issue area			
First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Larry	Camm			
19. Interest of each foreign e	ntity in the specific issues listed on line 16 above	Check if None		

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code VET

16. Specific lobbying issues

- Issues related to Veterans Administration and Veterans Health Administration policy, procurement, and contracting processes for medical technology.

17. House(s) of Congress and Federal agencies Check if None

U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Riley	Swinehart			
Jane	Adams			

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TRD

16. Specific lobbying issues

Issues related to: - Medical supply chains - TRIPS Waiver

17. House(s) of Congress and Federal agencies 🗌 Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Timothy	Swope			
David	Kavanaugh			
Jane	Adams			
Wendy	Sussman			
Riley	Swinehart			

LD-2 Disclosure Form

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CSP				
16. Specific lobbying issues				
Issues related to: - Counterfeit healthcare goods - Brand protection				
17. House(s) of Congress and Fed U.S. SENATE, U.S. HOUSE OF	5			
18. Name of each individual who	acted as a lobbyist in this issue area			
First Name Leif	Last Name Brierley	Suffix	Covered Official Position (if applicable)	New
19. Interest of each foreign entity	in the specific issues listed on line 16 above	e 🗹 Check if None		

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15	General	issue	area	code	SCI

16. Specific lobbying issues

S 3312 "Artificial Intelligence	Research, Innovation, and Accountability Ac	t" regarding all provisions		
Issues related to:	recomplete france and the second activity in the	, regarding an provisionsi		
 Data privacy 				
- Cybersecurity				
 Artificial intelligence 				
- Robotics				
17. House(s) of Congress and	Federal agencies 🗌 Check if None			
U.S. SENATE, U.S. HOUSE (OF REPRESENTATIVES			
18. Name of each individual w	ho acted as a lobbyist in this issue area			
First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Leif	Brierley			
		_		
19. Interest of each foreign ent	ity in the specific issues listed on line 16 abov	e 🗹 Check if None		

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code CPT

16. Specific lobbying issues

\$ 150, "Affordable Prescriptions for Patients Act of 2023", regarding all provisions.	
S 79/HR 1717, "Interagency Patent Coordination and Improvement Act of 2023", regarding all provisions.	
Issues related to intellectual property.	

17. House(s) of Congress and Federal agencies 🗌 Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Timothy	Swope			
David	Kavanaugh			
Jane	Adams			

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code TAX

16. Specific lobbying issues

\$ 866/HR 2673, "American Innovation and R&D Competitiveness Act of 2023", regarding provisions related to research & development expensing.
Issues related to:
- OECD proposals on global tax & implementation
- R&D expensing
- Corporate tax provisions in TCJA
- Corporate Alternative Minimum Tax implementation
17. House(s) of Congress and Federal agencies 🗌 Check if None
U.S. HOUSE OF REPRESENTATIVES, Treasury - Dept of
18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
David	Kavanaugh			
Jane	Adams			
Kelly	Waters			
Riley	Swinehart			

LD-2 Disclosure Form

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code PHA

16. Specific lobbying issues

- HR 4490, "To amend the Controlled Substances Act to authorize pharmacies to deliver certain controlled substances to an administering practitioner in lieu of delivering such substances to the to the ultimate user, and for other purposes", regarding all provisions. - Issues related to drug shortages.

17. House(s) of Congress and Federal agencies Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Amy	Pellegrino			
Wendy	Sussman			
Meghan	Stone			
Abigail	Pinkele			
Timothy	Swope			

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code ENV

16. Specific lobbying issues

Issues related to - Clean energy

Environmental sustainability Final Rule - U.S. EPA Rulemaking on National Emission Standards for Hazardous Air Pollutants (NESHAP) for Ethylene Oxide.

17. House(s) of Congress and Federal agencies 🗌 Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Kelly	Waters			
Riley	Swinehart			

LD-2 Disclosure Form

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code BNK

16. Specific lobbying issues

HR 5488, S 2805, "Protecting Our Courts from Foreign Manipulation Act of 2023", regarding provisions relating to transparency from foreign investors in US litigation.

Issues related to: - Chapter 11 corporate bankruptcy process - Litigation reform

17. House(s) of Congress and Federal agencies 🗌 Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Riley	Swinehart			
Kelly	Waters			
Abigail	Pinkele			
Larry	Camm			
Jane	Adams			

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code MMM	15.	General	issue	area	code	MMM	
---------------------------------	-----	---------	-------	------	------	-----	--

16. Specific lobbying issues

Issues related to the Medicaid Drug Rebate Program.

17. House(s) of Congress and Federal agencies 🗌 Check if None

U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Office of Management & Budget (OMB)

18. Name of each individual who acted as a lobbyist in this issue area

First Name	Last Name	Suffix	Covered Official Position (if applicable)	New
Amy	Pellegrino			
Wendy	Sussman			

LD-2 Disclosure Form

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.

15. General issue area code LAW				
16. Specific lobbying issues				
- HR 5488 and S 2805, the "Protecting our Courts - Issues related to transparency in third-party litiga		garding all provisions		
17. House(s) of Congress and Federal agencies	Check if None			
U.S. SENATE, U.S. HOUSE OF REPRESENTAT	IVES			
18. Name of each individual who acted as a lobby	ist in this issue area			
First Name La	st Name	Suffix	Covered Official Position (if applicable)	New
Jane	lams			
Riley Sw	vinehart			
19. Interest of each foreign entity in the specific is	sues listed on line 16 above 🖉 Ch	eck if None		
Information Update Page - Complete ONLY wh 20. Client new address	nere registration information has o	changed.		
Address				
City		State	Zip Code	Country
21. Client new principal place of business (if diffe	rent than line 20)			
City		State	Zip Code	Country
				Country
22. New General description of client's business o	r activities			
23. Name of each previously reported individual w First Name Last Nam 2 ISSUE UPDATE 24. General lobbying issue that no longer pertains AFFILIATED ORGANIZATIONS 25. Add the following affiliated organization(s) Internet Address:	ne	Suffix First Name	Last Name	Suffix
		Address		
Name	Street Address		(city and s	lace of Business state or country)
	City	State/Province Zip	Country City	
			State	Country
26. Name of each previously reported organization	that is no longer affiliated with the	registrant or client	1	
1	2		3	
FOREIGN ENTITIES				
27. Add the following foreign entities:				
	Address			

 Name
 Address
 Principal place of business (city and state or country)
 Amount of contribution for lobbying activities
 Ownership percentage in client

 City
 State/Province
 Country
 City
 City</t

Name	Address Street Address City State/Province Country	Principal place of business (city and state or country)	Amount of contribution for lobbying activities	Ownership percentage in client
		State Country		
28. Name of each previously reported foreign entit	ty that no longer owns, or controls, or is affiliate	d with the registrant, client or affiliated organization		
1 2	3 4	5 6		

CONVICTIONS DISCLOSURE

29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery, extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?

No Yes

Lobbyist Name	Description of Offense(s)
8	